217 related articles for article (PubMed ID: 12650794)
1. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective.
Longstreth GF; Wilson A; Knight K; Wong J; Chiou CF; Barghout V; Frech F; Ofman JJ
Am J Gastroenterol; 2003 Mar; 98(3):600-7. PubMed ID: 12650794
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
3. Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study.
Brun-Strang C; Dapoigny M; Lafuma A; Wainsten JP; Fagnani F
Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1097-103. PubMed ID: 17998835
[TBL] [Abstract][Full Text] [Related]
4. Costs of care for irritable bowel syndrome patients in a health maintenance organization.
Levy RL; Von Korff M; Whitehead WE; Stang P; Saunders K; Jhingran P; Barghout V; Feld AD
Am J Gastroenterol; 2001 Nov; 96(11):3122-9. PubMed ID: 11721759
[TBL] [Abstract][Full Text] [Related]
5. Is there a difference between abdominal pain and discomfort in moderate to severe IBS patients?
Sach J; Bolus R; Fitzgerald L; Naliboff BD; Chang L; Mayer EA
Am J Gastroenterol; 2002 Dec; 97(12):3131-8. PubMed ID: 12492200
[TBL] [Abstract][Full Text] [Related]
6. Medical costs in community subjects with irritable bowel syndrome.
Talley NJ; Gabriel SE; Harmsen WS; Zinsmeister AR; Evans RW
Gastroenterology; 1995 Dec; 109(6):1736-41. PubMed ID: 7498636
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome.
Creed F; Ratcliffe J; Fernandez L; Tomenson B; Palmer S; Rigby C; Guthrie E; Read N; Thompson D
Ann Intern Med; 2001 May; 134(9 Pt 2):860-8. PubMed ID: 11346322
[TBL] [Abstract][Full Text] [Related]
8. The economic consequences of irritable bowel syndrome: a US employer perspective.
Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of irritable bowel syndrome in China.
Zhang F; Xiang W; Li CY; Li SC
World J Gastroenterol; 2016 Dec; 22(47):10450-10460. PubMed ID: 28058026
[TBL] [Abstract][Full Text] [Related]
10. Defining and diagnosing irritable bowel syndrome.
Schuster MM
Am J Manag Care; 2001 Jul; 7(8 Suppl):S246-51. PubMed ID: 11474909
[TBL] [Abstract][Full Text] [Related]
11. The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome.
Spiegel BM; Kanwal F; Naliboff B; Mayer E
Am J Gastroenterol; 2005 Oct; 100(10):2262-73. PubMed ID: 16181379
[TBL] [Abstract][Full Text] [Related]
12. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain.
Nyrop KA; Palsson OS; Levy RL; Von Korff M; Feld AD; Turner MJ; Whitehead WE
Aliment Pharmacol Ther; 2007 Jul; 26(2):237-48. PubMed ID: 17593069
[TBL] [Abstract][Full Text] [Related]
13. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype.
Mearin F; Balboa A; Badía X; Baró E; Caldwell E; Cucala M; Díaz-Rubio M; Fueyo A; Ponce J; Roset M; Talley NJ
Eur J Gastroenterol Hepatol; 2003 Feb; 15(2):165-72. PubMed ID: 12560761
[TBL] [Abstract][Full Text] [Related]
14. The economic impact of irritable bowel syndrome in a managed care setting.
Patel RP; Petitta A; Fogel R; Peterson E; Zarowitz BJ
J Clin Gastroenterol; 2002 Jul; 35(1):14-20. PubMed ID: 12080220
[TBL] [Abstract][Full Text] [Related]
15. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
16. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
17. Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients.
Schmulson M; Chang L; Naliboff B; Lee OY; Mayer EA
Am J Gastroenterol; 2000 Jan; 95(1):152-6. PubMed ID: 10638575
[TBL] [Abstract][Full Text] [Related]
18. Patients suspected of irritable bowel syndrome--cross-sectional study exploring the sensitivity of Rome III criteria in primary care.
Engsbro AL; Begtrup LM; Kjeldsen J; Larsen PV; de Muckadell OS; Jarbøl DE; Bytzer P
Am J Gastroenterol; 2013 Jun; 108(6):972-80. PubMed ID: 23419383
[TBL] [Abstract][Full Text] [Related]
19. [Irritable bowel syndrome and healthcare consumption. An observational study in private gastroenterology].
Dapoigny M; Dyard F; Grimaud JC; Guyot P; van Ganse E
Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 1):265-71. PubMed ID: 12700510
[TBL] [Abstract][Full Text] [Related]
20. Pain symptoms and stooling patterns do not drive diagnostic costs for children with functional abdominal pain and irritable bowel syndrome in primary or tertiary care.
Lane MM; Weidler EM; Czyzewski DI; Shulman RJ
Pediatrics; 2009 Mar; 123(3):758-64. PubMed ID: 19254999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
